GLP-1 clinical studies

Published trials by medicine, population and endpoint, with results and original sources.

Clinical trial results at a glance

All weight charts

Phase 3b · 72 weeks

STEP UP

Wegovy injection

Mean body weight change

Semaglutide 7.2 mg: −18.7%
Semaglutide 2.4 mg: −15.6%
Placebo: −3.9%

Phase 3b · 72 weeks

SURMOUNT-5

MounjaroWegovy injection

Mean body weight change

Tirzepatide 10 or 15 mg: −20.2%
Semaglutide 1.7 or 2.4 mg: −13.7%

Phase 3b · 64 weeks

OASIS 4

Wegovy tablets

Mean body weight change

Oral semaglutide 25 mg: −13.6%
Placebo: −2.2%

Study register

7 of 19 studies

Search trialsMedicineOutcome

Study	Medicine	Population & follow-up	Published results	Source
SURMOUNT-5Phase 3b · 2025 · 751 participants MounjaroWegovy injectionWithout type 2 diabetes · 72 weeks	MounjaroWegovy injection	Without type 2 diabetes72 weeks	Mean body weight change at 72 weeks Tirzepatide 10 or 15 mg −20.2% Semaglutide 1.7 or 2.4 mg −13.7%	Paper
STEP UPPhase 3b · 2025 · 1,407 participants Wegovy injectionWithout diabetes · 72 weeks	Wegovy injection	Without diabetes72 weeks	Mean body weight change at 72 weeks Semaglutide 7.2 mg −18.7% Semaglutide 2.4 mg −15.6% Placebo −3.9%	Paper
REDEFINE 1Phase 3a · 2025 · 3,417 participants CagriSemaWegovy injectionWithout diabetes · 68 weeks	CagriSemaWegovy injection	Without diabetes68 weeks	Mean body weight change at 68 weeks CagriSema 2.4 mg / 2.4 mg −20.4% Semaglutide 2.4 mg −14.9% Cagrilintide 2.4 mg −11.5% Placebo −3.0%	Paper
SELECTPhase 3 · 2023 · 17,604 participants Wegovy injectionEstablished cardiovascular disease · 39.8 months	Wegovy injection	Established cardiovascular disease39.8 months	Participants with a major cardiovascular event over 39.8 months of mean follow-up Semaglutide 2.4 mg 6.5% Placebo 8.0%	Paper
STEP 5Phase 3 · 2022 · 304 participants Wegovy injectionWithout diabetes · 104 weeks	Wegovy injection	Without diabetes104 weeks	Mean body weight change at 104 weeks Semaglutide 2.4 mg −15.2% Placebo −2.6%	Paper
STEP 1Phase 3 · 2021 · 1,961 participants Wegovy injectionWithout diabetes · 68 weeks	Wegovy injection	Without diabetes68 weeks	Mean body weight change at 68 weeks Semaglutide 2.4 mg −14.9% Placebo −2.4%	Paper
STEP 4Phase 3 · 2021 · 803 participants Wegovy injectionAfter semaglutide lead-in · 48 weeks	Wegovy injection	After semaglutide lead-in48 weeks	Mean body weight change from week 20 to week 68 Continued semaglutide 2.4 mg −7.9% Switched to placebo +6.9%	Paper

Open a study to see doses, comparators and the exact endpoint.